Delisting riskPopularity #3,749
Lucid Diagnostics (LUCD)
Commercializes EsoGuard testing on esophageal cells collected with EsoCheck.
$0.8652
After hours−0.02 (−2.10%)
At close$0.8838(+4.58%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 |
| Cost of revenue | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 |
| Gross profit | −1 | 0 | −1 | −1 | −1 | −1 | −1 | −1 | 0 | 0 | −1 | 0 |
| 10 | 11 | 10 | 11 | 11 | 11 | 12 | 11 | 11 | 14 | 12 | 13 | |
| Research & development | 2 | 2 | 2 | 1 | 2 | 1 | 1 | 1 | 1 | 2 | 1 | 1 |
| 8 | 9 | 8 | 9 | 9 | 10 | 10 | 9,624 | 10 | 12 | 10,434 | 12 | |
| Selling & marketing | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4,007 | 4 | 5 | 5,002 | 6 |
| General & administrative | 4 | 4 | 4 | 5 | 5 | 6 | 6 | 5,617 | 6 | 6 | 5,432 | 6 |
| Other expenses | 1 | 1 | 0 | 0 | 0 | 0 | 0 | −9,614 | 0 | 0 | −10,424 | 0 |
| Operating income | −11 | −11 | −11 | −11 | −12 | −12 | −12 | −11 | −12 | −14 | −12 | −13 |
| −3 | 1 | 0 | 0 | −1 | 1 | −14 | 7 | 1 | −2 | −2 | 1 | |
| Interest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | 3 | −1 | 0 | 0 | 1 | −1 | 14 | −7 | −1 | 2 | 2 | −1 |
| Income before tax | −14 | −11 | −11 | −11 | −12 | −12 | −27 | −4 | −10 | −16 | −14 | −12 |
| Net income from continuing operations | −14 | −11 | −11 | −11 | −12 | −12 | −27 | −4 | −10 | −16 | −14 | −12 |
| Net income | −14 | −11 | −11 | −11 | −12 | −12 | −27 | −4 | −10 | −16 | −14 | −12 |
| EPS, basic | −$0.34 | −$0.26 | −$0.40 | −$0.23 | −$0.25 | −$0.20 | −$0.52 | −$0.08 | −$0.10 | −$0.12 | −$0.17 | −$0.08 |
| EPS, diluted | −$0.34 | −$0.26 | −$0.40 | −$0.23 | −$0.25 | −$0.20 | −$0.52 | −$0.08 | −$0.10 | −$0.12 | −$0.17 | −$0.08 |
| Weighted average shares, basic | 42 | 42 | 45 | 48 | 50 | 58 | 69 | 99 | 108 | 102 | 102 | 183 |
| Weighted average shares, diluted | 42 | 42 | 45 | 48 | 50 | 58 | 69 | 99 | 108 | 102 | 102 | 183 |
| EBITDA | −13 | −10 | −10 | −11 | −12 | −11 | −27 | −4 | −10 | −16 | −14 | −11 |
| Depreciation & amortization | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | −14 | −11 | −11 | −11 | −12 | −12 | −27 | −4 | −10 | −16 | −14 | −12 |
